Combined AI and Experimental Validation Platform Enables End-to-End Protein Binder Discovery in 1-2 Weeks The updates create a comprehensive, end-to-end system that enables protein binder discovery in ...
SAN CARLOS, Calif., June 11, 2025--(BUSINESS WIRE)--Diffuse Bio, a leading provider of AI systems for designing protein therapeutics, today announced the public launch of DSG2-mini, its latest AI ...
Hereditary cancer syndromes are disorders that increase your risk of certain cancers due to mutations in one or more genes inherited from your parents. Genetic testing can help you determine your risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results